Xofigo® (radium Ra-223 dichoride) has been a game-changer in the treatment of prostate cancer metastatic to bone. Not only does it provide significant pain palliation and reduce skeletal-related adverse events, but it slows down progression of the disease, increasing median survival by about 30 percent. … READ MORE …
Filed under: Living with Prostate Cancer, Management, Treatment | Tagged: antigen, J591, Lu-177, lutetium, membrane, PSMA, radiation, surface, systemic | 19 Comments »
THE "NEW" PROSTATE CANCER INFOLINK 